Ozempic vs Mounjaro 2026: Which GLP-1 Is Better for Weight Loss?

Two medications dominate the GLP-1 weight loss landscape in 2026: semaglutide (Ozempic, Wegovy, compounded semaglutide) and tirzepatide (Mounjaro, Zepbound). Here is a complete, evidence-based comparison covering mechanism, efficacy, side effects, cost, and availability.

Mechanism: GLP-1 vs Dual GIP/GLP-1

Semaglutide is a highly selective GLP-1 receptor agonist — it mimics the natural gut hormone GLP-1 to regulate appetite, blood sugar, and gastric emptying. Tirzepatide adds a second receptor target: GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are expressed in adipose tissue, the pancreas, and the brain. Activating both GIP and GLP-1 simultaneously appears to produce additive effects on appetite suppression, fat metabolism, and insulin sensitivity — explaining why tirzepatide outperforms semaglutide in head-to-head data.

Weight Loss Efficacy: The Numbers

The STEP-1 trial (semaglutide 2.4mg, 68 weeks): average weight loss of 14.9% of body weight. The SURMOUNT-1 trial (tirzepatide 15mg, 72 weeks): average weight loss of 20.9%. The SURMOUNT-5 head-to-head trial (2024) directly compared the two: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide — a statistically significant difference. For absolute maximum average weight loss, tirzepatide wins.

Cardiovascular Evidence

Semaglutide holds a decisive advantage here. The SELECT trial (2023) enrolled 17,604 adults with obesity and established cardiovascular disease and demonstrated a 20% reduction in MACE (heart attack, stroke, CV death) with semaglutide — a landmark finding that changed treatment guidelines. Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) was still reporting as of early 2026. For patients with existing heart disease, semaglutide is currently the evidence-backed choice for CV risk reduction.

Side Effects

Both medications cause predominantly GI side effects: nausea (most common), diarrhoea, vomiting, and constipation. These are dose-dependent and improve with slower titration. Nausea affects approximately 44% of semaglutide users versus 31% of tirzepatide users in trial data — a genuine though modest tolerability advantage for tirzepatide. Both carry a class warning for thyroid C-cell tumours (based on rodent data) and pancreatitis risk monitoring. Injecting weekly, both produce similar injection site tolerability.

Cost & Access in 2026

This is where semaglutide holds its strongest practical advantage. Brand-name Wegovy and Zepbound cost $1,000–$1,400/month without insurance. Compounded semaglutide from telehealth providers is available at $149–$350/month. Compounded tirzepatide became legally and practically restricted from late 2024 as the FDA removed tirzepatide from its drug shortage list — compounding pharmacies can no longer legally produce it at scale. In 2026, accessible affordable tirzepatide is largely unavailable without insurance. Semaglutide via compounding remains the affordable route for most people.

The Verdict: Which Should You Choose?

Choose semaglutide if: you want the most accessible, affordable option via compounding; you have established cardiovascular disease and want the strongest CV outcome evidence; or your physician recommends it as first-line. Consider tirzepatide if: maximum weight loss is your primary goal and you have insurance coverage; you have tried semaglutide and had an inadequate response; or your physician has access to brand-name Zepbound at a manageable cost. For most people without insurance, semaglutide is the realistic and excellent choice in 2026.

Affiliate disclosure: Affiliate links present. See our Affiliate Disclosure.